Evidence map›Paper›PMID 36557291›Full record

ArticleMetabolites2022

Target Metabolites to Slow Down Progression of Amyotrophic Lateral Sclerosis in Mice.

Destiny Ogbu, Yongguo Zhang, Katerina Claud, Yinglin Xia, Jun Sun

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Microbiome and micronutrient in ALS: From novel mechanisms to new treatments.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  12. Review
  13. Review
  14. Intestinal Barrier Function and Neurodegenerative Disease.CNS & neurological disorders drug targets · 2024
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Destiny OgbuDepartment of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-3000-4032
Yongguo ZhangDepartment of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
Katerina ClaudDepartment of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
Yinglin XiaDepartment of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-6857-7437
Jun SunDepartment of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.ORCID 0000-0001-7465-3133
University of Illinois Chicago · US

Funding

How Vitamin D Receptor Influences Intestinal BarriersR01DK114126 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Jun Sun · 2018 to 2026
$3.0M
Vitamin D Receptor Regulation of Microbiota in Intestinal EpitheliaR01DK105118 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SUN, JUN · 2016 to 2020
$1.8M
Microbiome and intestinal barrier in ALS therapyI01BX004824 · VA · JESSE BROWN VA MEDICAL CENTER · PI SUN, JUN · 2020 to 2025
–
BLRD VA I01 BX004824Department of Defence BC191198National Institute of Health DK105118, and R01DK114126NIDDK/National Institutes of Health DOD CDMRP W81XWH-20-1-0623 (BC191198), DOD BC160450P1NIDDK NIH HHS R01 DK105118NIDDK NIH HHS R01 DK114126Veterans for America VA 1 I01BX004824-01
6 · The paper itself

Abstract

Microbial metabolites affect the neuron system and muscle cell functions. Amyotrophic lateral sclerosis (ALS) is a multifactorial neuromuscular disease. Our previous study has demonstrated elevated intestinal inflammation and dysfunction of the microbiome in patients with ALS and an ALS mouse model (human-SOD1

Indexed as

ALSCNSdysbiosisFALSimmunityinflammationlongitudinal analysismetabolitesneuromuscular diseaseprotein aggregationSALS

Identifiers

PMID36557291
PMCPMC9784240
OpenAlexW4312125952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.